VHL tumor suppressor gene and the initiation of renal cell carcinoma

VHL抑癌基因与肾细胞癌的发生

• 批准号: 8106922
• 负责人: TIEN HSU
• 金额: $ 32.85万
• 依托单位: BOSTON MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-07-01 至 2016-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8106922
• 关键词: Accounting; Adaptor Signaling Protein; Adult; Biological Assay; Cancer Biology; Cancer Model; Cell Culture Techniques; Cells; Cessation of life; Characteristics; Clear Cell; Complex; Conditioned Culture Media; Defect; Development; Disease; Disseminated Malignant Neoplasm; Drosophila genus; Early Diagnosis; Epigenetic Process; Erythropoietin; Event; Excision; Familial Polycythemia; Fibrosis; Funding; Gene Expression; Gene Expression Profiling; Genes; Genetic; Genetic Epistasis; Genetic Markers; Genetic Models; Germ Lines; Glucose; Glycolysis; Human; Hypoxia Inducible Factor; In Vitro; Incidence; Inflammation; Injury; Kidney; Knock-out; Knockout Mice; Lasers; Lesion; Loss of Heterozygosity; Malignant Epithelial Cell; Malignant Neoplasms; Metabolic; Metabolic Pathway; Metastatic to; Modeling; Molecular; Molecular Profiling; Mus; Mutation; Names; Operative Surgical Procedures; Pathway interactions; Patients; Pattern; Premalignant; Preventive; Primary Lesion; Process; Procollagen-Proline Dioxygenase; Proteins; Radiation; Relapse; Renal Cell Carcinoma; Renal carcinoma; Renal tubule structure; Reporter Genes; Role; Signal Transduction; Somatic Mutation; Survival Rate; Symptoms; System; Therapeutic; Time; Tissues; Tumor Suppressor Genes; Uncertainty; United States; VHL gene; VHL mutation; Vascular Endothelial Growth Factors; Von Hippel-Lindau Syndrome; attributable mortality; cancer cell; cancer type; cell type; chemokine; cytokine; design; epithelial to mesenchymal transition; expectation; in vivo; kidney cell; mouse model; mutant; mutant mouse model; novel; protein degradation; statistics; tumor; tumor initiation; tumor progression; tumorigenesis; tumorigenic; ubiquitin-protein ligase

DESCRIPTION (provided by applicant): There are presently about 39,000 new cases of renal cancer in the United States each year, resulting in over 13,000 deaths. Traditional radiation and chemo-therapies are ineffective. Early detection is also difficult because of a lack of early symptoms. 40-50% of patients develop metastatic disease, for whom the 5-year survival rate is only ~10%. Such grim statistics point to an urgent need for better understanding of the kidney cancer biology. One important characteristic of kidney cancer is its strong association with lesions in one gene, the von Hippel-Lindau (VHL) tumor suppressor gene. The gene is named after the familial VHL disease. Up to 70% of the carriers of germ line VHL mutations develop renal cell carcinoma of the clear-cell type (ccRCC). In addition, loss of VHL function, including somatic mutations and epigenetic defects, is found in 70-90% of sporadic ccRCC. The best-documented function of VHL is its E3 ubiquitin ligase activity that targets the alpha subunit of the hypoxia-inducible factor (HIF-a). However, VHL also possess multiple HIF-independent functions. It is not known how loss of the complex spectrum of VHL functions collectively contribute to the initiation of ccRCC. The uncertainties are further compounded by a lack of VHL cancer model in mouse. Our studies in the past funding period have elucidated a novel epithelial-to-mesenchymal transition (EMT) pathway that has been implicated in kidney injury and fibrosis. Most importantly, using a new conditional knockout strategy, we have, for the first time, developed a genuine mouse ccRCC model that recapitulates features of kidney inflammation and fibrosis, leading to metastatic ccRCC. This model should allow us to elucidate the earliest event in ccRCC and point to potential preventive and curative strategies for this deadly disease. Four Specific Aims are proposed to characterize the new VHL cancer model: Aim 1. To determine the tissue origin and the role of VHL-HIF axis in VHL knockout lesions. Aim 2. To elucidate the molecular and cellular mechanisms of EMT signaling in VHL mutant cells. Aim 3. To elucidate the mechanism of inflammation in VHL mutant kidney. Aim 4. To profile the gene expression pattern associated with VHL tumor progression. PUBLIC HEALTH RELEVANCE: Mutations in VHL tumor suppressor gene are the cause of a majority of kidney cancers, but the exact tumorigenic mechanism of this deadly disease is still unknown. We recently developed a VHL mutant mouse model that for the first time, generated kidney cancer and suggested an intriguing possibility of inflammation prior to tumor development. Our proposed study should shed lights on the process of kidney cancer formation and point to preventive and curative strategies.

描述(申请人提供)：目前美国每年约有39,000例新的肾癌病例，导致超过13,000人死亡。传统的放疗和化疗都是无效的。由于缺乏早期症状，早期发现也很困难。40-50%的患者发生转移性疾病，其5年生存率仅为10%。如此严峻的统计数据表明，迫切需要更好地了解肾癌的生物学。肾癌的一个重要特征是它与一个基因的病变密切相关，即von Hippel-Lindau(VHL)肿瘤抑制基因。该基因是以家族性VHL疾病命名的。高达70%的生殖系VHL突变携带者发展为透明细胞型肾癌(CcRCC)。此外，在70-90%的散发性肾癌中发现VHL功能丧失，包括体细胞突变和表观遗传学缺陷。VHL最有文献记载的功能是它的E3泛素连接酶活性，它以缺氧诱导因子(HIF-a)的阿尔法亚单位为靶标。然而，VHL也具有多种HIF非依赖功能。目前尚不清楚VHL功能复合谱的丢失如何共同促进ccRCC的启动。由于缺乏小鼠VHL肿瘤模型，这种不确定性进一步加剧。我们在过去的资助时期的研究阐明了一种新的上皮向间充质转化(EMT)途径，该途径与肾脏损伤和纤维化有关。最重要的是，使用新的条件性基因敲除策略，我们首次开发了真正的小鼠ccRCC模型，该模型概括了导致转移性ccRCC的肾脏炎症和纤维化的特征。这一模型应该使我们能够阐明慢性肾细胞癌的最早事件，并指出这种致命疾病的潜在预防和治疗策略。目的1.确定VHL-HIF轴在VHL基因敲除病变中的组织起源和作用。目的2.阐明VHL突变细胞中EMT信号转导的分子和细胞机制。目的3.阐明VHL突变肾的炎症机制。目的4.研究与VHL肿瘤进展相关的基因表达谱。 公共卫生相关性：VHL肿瘤抑制基因突变是大多数肾癌的原因，但这种致命疾病的确切致癌机制仍不清楚。我们最近开发了一种VHL突变小鼠模型，该模型首次产生肾癌，并提出了在肿瘤发展之前发生炎症的有趣可能性。我们提出的研究应该有助于阐明肾癌的形成过程，并指出预防和治疗策略。